Abstract:Hossein Zare, 1, 2 Sepideh Ahmadi, 3, 4 Amir Ghasemi, 5 Mohammad Ghanbari, 6 Navid Rabiee, 7 Mojtaba Bagherzadeh, 7 Mahdi Karimi, 8– 11 Thomas J Webster, 12 Michael R Hamblin, 13 Ebrahim Mostafavi 12, 14, 15 1 Advances Nanobiotechnology and Nanomedicine Research Group (ANNRG), Iran University of Medical Sciences, Tehran, Iran; 2 Biomaterials Group, Materials Science and Engineering Department, Iran University of Science and Technology, Tehran, Iran; 3 Student Research Committee, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 4 Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 5 Department of Engineering, Durham University, Durham, DH1 3LE, United Kingdom; 6 School of Metallurgy and Materials Engineering, University of Tehran, Tehran, Iran; 7 Department of Chemistry, Sharif University of Technology, Tehran, Iran; 8 Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran; 9 Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran; 10 Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran; 11 Research Center for Science and Technology in Medicine, Tehran University of Medical Sciences, Tehran, MA, Iran; 12 Applied Biotechnology Research Centre, Tehran Medical Science, Islamic Azad University, Tehran, MA, Iran; 13 Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein, 2028, South Africa; 14 Stanford Cardiovascular Institute, Stanford, CA, USA; 15 Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA Correspondence: Ebrahim Mostafavi Stanford Cardiovascular Institute, Stanford University School of Medicine, Biomedical Innovation Building, 240 Pasteur Dr, Palo Alto, CA, 94304, USA Email ebimsv@stanford.edu Michael R Hamblin Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein, 2028, South Africa Email hamblin.lab@gmail.com The unique properties of carbon nanotubes (CNTs) (such as their high surface to volume ratios, enhanced conductivity and strength, biocompatibility, ease of functionalization, optical properties, etc.) have led to their consideration to serve as novel drug and gene delivery carriers. CNTs are effectively taken up by many different cell types through several mechanisms. CNTs have acted as carriers of anticancer molecules (including docetaxel (DTX), doxorubicin (DOX), methotrexate (MTX), paclitaxel (PTX), and gemcitabine (GEM)), anti-inflammatory drugs, osteogenic dexamethasone (DEX) steroids, etc. In addition, the unique optical properties of CNTs have led to their use in a number of platforms for improved photo-therapy. Further, the easy surface functionalization of CNTs has prompted their use to deliver different genes, such as plasmid DNA (PDNA), micro-RNA (miRNA), and small interfering RNA (siRNA) as gene delivery vectors for various diseases such as cancers. However, despite all of these promises, the most important continuous concerns raised by scientists reside in CNT nanotoxicology and the environmental effects of CNTs, mostly because of their non-biodegradable state. Despite a lack of widespread FDA approval, CNTs have been studied for decades and plenty of in vivo and in vitro reports have been published, which are reviewed here. Lastly, this review covers the future research necessary for the field of CNT medicine to grow even further. Keywords: drug delivery, gene delivery, carbon nanotube, precision medicine

Carbon Nanotubes As A Protein Toxin Transporter For Selective Her2-Positive Breast Cancer Cell Destruction

Tracking the endocytic pathway of recombinant protein toxin delivered by multiwalled carbon nanotubes.

Covalently Combining Carbon Nanotubes with Anticancer Agent: Preparation and Antitumor Activity

Synergistic Enhancement of Antitumor Efficacy by PEGylated Multi-walled Carbon Nanotubes Modified with Cell-Penetrating Peptide TAT.

Carbon Nanotubes as Intracellular Protein Transporters: Generality and Biological Functionality

Drug delivery with carbon nanotubes for in vivo cancer treatment

Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction

Primary Evaluation of Peptide Ligand Functionalized Multiwalled Carbon Nanotubes As Tumor Targeting Cells Carrier

In silico-guided discovery and in vitro validation of novel sugar-tethered lysinated carbon nanotubes for targeted drug delivery of doxorubicin

Carbon Nanotube-Mediated Delivery of PTEN Variants: In Vitro Antitumor Activity in Breast Cancer Cells

Proteomic Analysis of Cellular Response Induced by Multi-Walled Carbon Nanotubes Exposure in A549 Cells.

Magnetically Controllable Polymer Nanotubes from a Cyclized Crosslinker for Site-Specific Delivery of Doxorubicin

Carbon Nanotubes Conjugated to Tumor Lysate Protein Enhance the Efficacy of an Antitumor Immunotherapy.

Irradiation-Mediated Carbon Nanotubes Use In Cancer Therapy

Theranostics: aptamer-assisted carbon nanotubes as MRI contrast and photothermal agent for breast cancer therapy

Carbon Nanotubes: Smart Drug/Gene Delivery Carriers

Hierarchical Nanoassemblies-Assisted Combinational Delivery of Cytotoxic Protein and Antibiotic for Effective Cancer Treatment.

Magnetic Lymphatic Targeting Drug Delivery System Using Carbon Nanotubes

An Intelligent DNA Nanorobot with in Vitro Enhanced Protein Lysosomal Degradation of HER2.

Multi-functionalized single-walled carbon nanotubes as delivery carriers: promote the targeting uptake and antitumor efficacy of doxorubicin

Co-application of Ricin A Chain and a Recombinant Adenovirus Expressing Ricin B Chain As a Novel Approach for Cancer Therapy